Biocept NGS Breast Panel

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations.